Definium Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Definium Therapeutics, Inc.'s free cash flow has decreased 66.26% from $-79.13M last year to $-131.56M, signaling decreasing performance

Definium Therapeutics, Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability.

Definium Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.09 last year to 0.04 today, signaling strengthened financials

Definium Therapeutics, Inc. has a net cash position, so leverage is healthy.

Definium Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Definium Therapeutics, Inc. has insufficient data to evaluate this check.

Definium Therapeutics, Inc.'s short-term assets of $419.32M exceed its short-term liabilities of $66.70M

Definium Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Definium Therapeutics, Inc.'s return on equity of -85.23%, is lower than 15.00%, indicating bad performance

Definium Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Definium Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Definium Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Definium Therapeutics, Inc. has negative free cash flow, indicating cash burn

Definium Therapeutics, Inc.'s yearly earnings has decreased 69.12% since last year from $-108.68M to $-183.79M, signaling decreasing performance

Definium Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -23.81% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Definium Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Definium Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Definium Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Definium Therapeutics, Inc. has insufficient data to evaluate this check.

Definium Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Definium Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Definium Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Definium Therapeutics, Inc. has insufficient data to evaluate this check.

Definium Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Definium Therapeutics, Inc. has a price-to-book ratio of 5.44x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Definium Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue